Fertility and Sterility
Volume 93, Issue 4 , Pages 1169-1172 , 1 March 2010

An investigation of the visual disturbances experienced by patients on clomiphene citrate

  • Lyne Racette, Ph.D.

      Affiliations

    • The University of Ottawa Eye Institute, Ottawa, Ontario, Canada
    • Corresponding Author InformationReprint requests: Lyne Racette, Ph.D., Hamilton Glaucoma Center, Department of Ophthalmology, University of California at San Diego, 9500 Gilman Drive 0946, La Jolla, CA 92093-0946 (FAX: 858-822-0615).
    • ,
  • Peter R. Casson, M.D.

      Affiliations

    • University of Vermont, Fletcher Allen Health Care, Burlington, Vermont
    • ,
  • Paul Claman, M.D.

      Affiliations

    • The Ottawa Hospital, Civic Campus Parkdale Clinic, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Ottawa, Ontario, Canada
    • ,
  • David H. Zackon, M.D.

      Affiliations

    • The University of Ottawa Eye Institute, Ottawa, Ontario, Canada
    • ,
  • Evanne J. Casson, Ph.D.

      Affiliations

    • The University of Ottawa Eye Institute, Ottawa, Ontario, Canada

Received 6 September 2008 ,Revised 5 November 2008 ,Accepted 18 November 2008.

References 

  1. Greenblatt RB, Barfield WE, Jungck EC, Ray AW. Induction of ovulation with MRL/41. Preliminary report. JAMA. 1961;178:101–104
  2. Speroff L, Kase NG, Glass RH. Clinical gynecologic endocrinology and infertility. Baltimore, MD: Lippincott Williams & Wilkins; 1999;1098–105
  3. Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action—a hypothesis revisited. Fertil Steril. 1984;42:331–344
  4. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997;3:359–365
  5. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol. 1996;14:1018–1026
  6. Clomiphene from http://www.rxlist.com/cgi/generic/clomiph_ad.htm Retrieved September 19, 2006
  7. Lawton AW. Optic neuropathy associated with clomiphene citrate therapy. Fertil Steril. 1994;61:390–391
  8. Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol. 1995;113:482–484
  9. Bender MB, Feldman M, Sobin AJ. Palinopsia. Brain. 1968;91:321–338
  10. Regan D, Neima D. Low-contrast letter charts as a test of visual function. Ophthalmology. 1983;90:1192–1200
  11. Anderson DR, Patella VM. Automated static perimetry. 2nd ed. St. Louis, MO: CV Mosby; 1999;
  12. Casson EJ, Johnson CA, Shapiro LR. Longitudinal comparison of temporal-modulation perimetry with white-on-white and blue-on-yellow perimetry in ocular hypertension and early glaucoma. J Opt Soc Am A Opt Image Sci Vis. 1993;10:1792–1806
  13. Hardy LH, Rand G, Rittler MC. The H-R-R polychromatic plates. I.A. test for the detection, classification, and estimation of the degree of defective color vision. AMA Arch Ophthalmol. 1954;51:216–228
  14. Roch LM, Gordon DL, Barr AB, Paulsen CA. Visual changes associated with clomiphene citrate therapy. Arch Ophthalmol. 1967;77:14–17
  15. Rock T, Dinar Y, Romem M. Retinal periphlebitis after hormonal treatment. Ann Ophthalmol. 1989;21:75–76
  16. Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006;106:505–513
  17. Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye. 1997;11(Pt 3):295–297
  18. Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye. 1999;13(Pt 6):729–733
  19. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315–320
  20. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology. 1981;88:89–93

 L.R. has nothing to disclose. P.R.C. has nothing to disclose. P.C. has nothing to disclose. D.H.Z. has nothing to disclose. E.J.C. has nothing to disclose.

 Supported by the University of Ottawa Faculty of Medicine Research Fund.

 The present address for Dr. Racette is Hamilton Glaucoma Center, Department of Ophthalmology, University of California at San Diego, 9500, Gilman Drive 0946, La Jolla CA 92093-0946.

 The present address for Dr. Claman is Ottawa Fertility Center, Department of Obstetrics and Gynecology, Division of Reproductive Medicine, University of Ottawa, 955 Green Valley Crescent, Ottawa, Ontario, K2C 3V4 Canada.

PII: S0015-0282(08)04583-4

doi: 10.1016/j.fertnstert.2008.11.025

Fertility and Sterility
Volume 93, Issue 4 , Pages 1169-1172 , 1 March 2010

Article Tools

* Image Usage & Resolution